{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:12:04Z","timestamp":1759342324019,"version":"3.37.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.lpm.2009.02.006","type":"journal-article","created":{"date-parts":[[2009,4,6]],"date-time":"2009-04-06T08:44:23Z","timestamp":1239007463000},"page":"761-773","source":"Crossref","is-referenced-by-count":5,"title":["Traitements anti-TNF\u03b1 dans les maladies auto-immunes et\/ou inflammatoires syst\u00e9miques"],"prefix":"10.1016","volume":"38","author":[{"given":"Alexis","family":"R\u00e9gent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2009.02.006_bib1","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib2","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib3","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis\u00a0:a randomized, placebo-controlled study","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2009.02.006_bib4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0755-4982(06)74658-9","article-title":"Anti-TNF alpha dans le traitement du rhumatisme psoriasique","volume":"35","author":"Claudepierre","year":"2006","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib5","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis\u00a0: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2009.02.006_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone\u00a0: a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib7","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib9","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis\u00a0: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/ard.62.11.1116","article-title":"Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis","volume":"62","author":"Andonopoulos","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/ard.62.4.373","article-title":"Successful treatment of resistant giant cell arteritis with etanercept","volume":"62","author":"Tan","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s10067-006-0375-2","article-title":"Treatment of refractory temporal arteritis with adalimumab","volume":"26","author":"Ahmed","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis\u00a0: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2169\/internalmedicine.45.1377","article-title":"Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate","volume":"45","author":"Tanaka","year":"2006","journal-title":"Intern Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib16","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/rheumatology\/keh661","article-title":"Two Takayasu arteritis patients successfully treated with infliximab\u00a0: a potential disease-modifying agent?","volume":"44","author":"Della Rossa","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib17","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffman","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib18","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/ard.2008.093260","article-title":"Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis\u00a0: long-term follow-up","volume":"67","author":"Molloy","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib19","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides\u00a0: an open pilot study on 10 patients","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/ard.2007.083584","article-title":"Infliximab efficacy and safety against refractory systemic necrotising vasculitides\u00a0: long-term follow-up of 15 patients","volume":"67","author":"Josselin","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib21","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/ard.61.6.559","article-title":"Safety and efficacy of TNFalpha blockade in relapsing vasculitis","volume":"61","author":"Booth","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","article-title":"Etanercept combined with conventional treatment in Wegener's granulomatosis\u00a0: a six-month open-label trial to evaluate safety","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib24","unstructured":"Guillevin L, Cohen P, Pagnoux C, Mahr A, Cottin V, Buchler M et al. Comparison of Infliximab and Rituximab in Wegener's Granulomatosis (WG) Refractory to Steroids and Immunosuppressants\u00a0: a Prospective, Randomized Study on 21 Patients. Arthritis Rheum 2008;abstract 1873."},{"key":"10.1016\/j.lpm.2009.02.006_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib26","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00296-008-0592-x","article-title":"Improved rheumatoid digital vasculitis in a patient treated with TNFalpha agent blocking (infliximab)","volume":"28","author":"Benucci","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.lpm.2009.02.006_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/rheumatology\/41.2.234","article-title":"Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor alpha monoclonal antibody infliximab","volume":"41","author":"Garcia-Porrua","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ard.62.6.587","article-title":"Successful treatment of severe rheumatoid vasculitis by infliximab","volume":"62","author":"Unger","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib29","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/rheumatology\/39.12.1436","article-title":"Mononeuritis secondary to rheumatoid arthritis responds to etanercept","volume":"39","author":"Richter","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib30","first-page":"759","article-title":"Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab","volume":"32","author":"Armstrong","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0151-9638(06)70938-3","article-title":"Vasculite avec ulc\u00e9rations cutan\u00e9es au cours de la polyarthrite rhumato\u00efde : traitement par anti TNF","volume":"133","author":"Thirion","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.lpm.2009.02.006_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2007.081679","article-title":"Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis","volume":"67","author":"Puechal","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib33","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","article-title":"Effect of infliximab on threatening panuveitis in Behcet's disease","volume":"358","author":"Munoz-Fernandez","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2009.02.006_bib34","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0755-4982(05)84079-5","article-title":"Infliximab in the treatment of posterior uveitis in Behcet's disease. Long term follow up in four patients","volume":"34","author":"Lanthier","year":"2005","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease","volume":"26","author":"Abu El-Asrar","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.lpm.2009.02.006_bib36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","article-title":"Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab)","volume":"19","author":"Benitez-del-Castillo","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.lpm.2009.02.006_bib37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.lpm.2009.02.006_bib38","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib39","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib40","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","article-title":"Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects","volume":"1110","author":"Tognon","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.lpm.2009.02.006_bib41","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Behcet's disease","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.lpm.2009.02.006_bib43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","article-title":"Infliximab for the treatment of Neuro-Behcet's disease: a case series and review of the literature","volume":"59","author":"Pipitone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib44","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1365-2133.2005.06914.x","article-title":"Infliximab treatment for severe orogenital ulceration in Behcet's disease","volume":"153","author":"Connolly","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib45","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/ard.2003.010975","article-title":"Successful treatment of genital ulcers with infliximab in Behcet's disease","volume":"63","author":"Haugeberg","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib46","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaad.2004.11.031","article-title":"A case of mucocutaneous Behcet's disease responding to etanercept","volume":"52","author":"Sommer","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib47","first-page":"98","article-title":"Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib48","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sjogren's syndrome: a pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib49","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1002\/art.10674","article-title":"Infliximab in primary Sjogren's syndrome: one-year followup","volume":"46","author":"Steinfeld","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib50","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib51","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib52","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/ard.2007.077891","article-title":"Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation","volume":"67","author":"Moutsopoulos","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib53","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib54","first-page":"1802","article-title":"Use of etanercept in the treatment of dermatomyositis: a case series","volume":"33","author":"Iannone","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib55","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib56","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000114036","article-title":"Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate","volume":"59","author":"Hengstman","year":"2008","journal-title":"Eur Neurol"},{"key":"10.1016\/j.lpm.2009.02.006_bib57","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/rheumatology\/kem205","article-title":"Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab","volume":"46","author":"Ideguchi","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib58","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10165-007-0006-z","article-title":"Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome","volume":"18","author":"Takahashi","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib59","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s10067-006-0219-0","article-title":"Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis","volume":"26","author":"Hayat","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s10165-006-0561-8","article-title":"Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus","volume":"17","author":"Hayat","year":"2007","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib61","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib62","unstructured":"Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008; 0: ard.2008.096123v1."},{"key":"10.1016\/j.lpm.2009.02.006_bib63","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/rheumatology\/keg341","article-title":"Pancytopenia in a patient with scleroderma treated with infliximab","volume":"42","author":"Menon","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib64","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s10067-006-0229-y","article-title":"A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap\/rheumatoid arthritis","volume":"26","author":"Hamaguchi","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib65","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2005.044453","article-title":"Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab","volume":"65","author":"Allanore","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib66","article-title":"Treatment of refractory neurosarcoidosis with infliximab","author":"Santos","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2009.02.006_bib67","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00296-007-0359-9","article-title":"Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab","volume":"27","author":"Cruz","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.lpm.2009.02.006_bib68","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2133.2004.05769.x","article-title":"Infliximab therapy for sarcoidosis (lupus pernio)","volume":"150","author":"Haley","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib69","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10067-005-0037-9","article-title":"Treatment of therapy-resistant sarcoidosis with adalimumab","volume":"25","author":"Callejas-Rubio","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib70","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","article-title":"Treatment of sarcoidosis with infliximab","volume":"127","author":"Doty","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2009.02.006_bib71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2009.02.006_bib72","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib73","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2009.02.006_bib74","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10067-004-1064-7","article-title":"Prolonged remission in adult-onset Still's disease with etanercept","volume":"25","author":"Kumari","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib75","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/rheumatology\/kem066","article-title":"Adult-onset Still's disease and myocarditis: successful treatment with intravenous immunoglobulin and maintenance of remission with etanercept","volume":"46","author":"Kuek","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10067-003-0744-z","article-title":"Infliximab in a case of early adult-onset Still's disease","volume":"22","author":"Olivieri","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10067-003-0775-5","article-title":"Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients","volume":"23","author":"Kokkinos","year":"2004","journal-title":"Clin Rheumatol"},{"issue":"Suppl 3","key":"10.1016\/j.lpm.2009.02.006_bib78","doi-asserted-by":"crossref","first-page":"iii55","DOI":"10.1136\/ard.60.90003.iii55","article-title":"Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences","volume":"60","author":"Kraetsch","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib79","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/art.10231","article-title":"Etanercept in the treatment of adult patients with Still's disease","volume":"46","author":"Husni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib80","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib81","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/art.10581","article-title":"Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab","volume":"46","author":"Elkayam","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib82","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s10067-007-0679-x","article-title":"Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients","volume":"26","author":"Kobak","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib83","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/rheumatology\/keh357","article-title":"Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome","volume":"43","author":"Drewe","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib84","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/art.11163","article-title":"Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy","volume":"48","author":"Gottenberg","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib85","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/ard.2003.016733","article-title":"Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS)","volume":"63","author":"Lamprecht","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib86","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mpd.2003.15","article-title":"A new mutation causing autosomal dominant periodic fever syndrome in a Danish family","volume":"142","author":"Weyhreter","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.lpm.2009.02.006_bib87","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0952-7915(00)00124-2","article-title":"TNFRSF1A mutations and autoinflammatory syndromes","volume":"12","author":"Galon","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.lpm.2009.02.006_bib88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/rheumatology\/keg070","volume":"42","author":"Drewe","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib89","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/rheumatology\/kel298","article-title":"Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS)","volume":"46","author":"Jacobelli","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.02.006_bib90","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.amjmed.2004.02.039","article-title":"Beneficial response to interleukin 1 receptor antagonist in traps","volume":"117","author":"Simon","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2009.02.006_bib91","doi-asserted-by":"crossref","unstructured":"Lanfant-Weybel K, Lequerr\u00e9 T, Vittecoq O. Anti-TNF alpha dans le traitement de la polyarthrite rhumato\u00efde et de la spondylarthrite ankylosante. Presse Med 2009;Sous presse.","DOI":"10.1016\/j.lpm.2009.02.003"},{"key":"10.1016\/j.lpm.2009.02.006_bib92","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1191\/0961203305lu2240rr","article-title":"The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications","volume":"14","author":"De Rycke","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.lpm.2009.02.006_bib93","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2009.02.006_bib94","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/ard.2003.018093","article-title":"Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies","volume":"63","author":"Jonsdottir","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib95","first-page":"546","article-title":"Arterial thrombosis with anti-phospholipid antibodies induced by infliximab","volume":"17","author":"Nosbaum","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib96","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib97","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/ard.2005.043208","article-title":"Guillain-Barre syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature","volume":"67","author":"Silburn","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.02.006_bib98","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1212\/01.WNL.0000142974.81103.95","article-title":"Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy","volume":"63","author":"Singer","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2009.02.006_bib99","article-title":"Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new \u201cclass effect\u201d paradoxical phenomenon. two case reports and literature review","author":"Massara","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.02.006_bib100","first-page":"349","article-title":"Granulomatous hepatitis associated with etanercept therapy","volume":"35","author":"Farah","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib101","first-page":"1467","article-title":"Giant cell arteritis in a patient taking etanercept and methotrexate","volume":"31","author":"Seton","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib102","first-page":"532","article-title":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept","volume":"35","author":"Song","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2009.02.006_bib103","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498209000980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498209000980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T21:25:02Z","timestamp":1739049902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498209000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0755498209000980"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2009.02.006","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}